NORTH HOLLYWOOD, Calif.--(BUSINESS WIRE)-- The International Myeloma Foundation (IMF) – the oldest and largest foundation dedicated to improving the life and care of myeloma patients – says three studies demonstrating that long term maintenance treatment “significantly improves outcome” and more than doubles remission times, have been published together in the New England Journal of Medicine. The articles cover the use of continuous treatment with the oral drug REVLIMID® both in newly diagnosed patients and following stem cell transplants. Although the findings have been presented separately at medical conferences this marks their first publication together in a scientific “peer reviewed” journal, an indication of the importance of these findings.
